← Back to Search

Monoclonal Antibodies

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Phase 1
Waitlist Available
Research Sponsored by Viela Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 85

Summary

This trial tests if a drug is safe and tolerable for people with autoimmune diseases.

Eligible Conditions
  • Connective tissue diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 85
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 85 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Treatment-Emergent Adverse Event
Secondary study objectives
Anti-drug antibodies
Pharmacodynamics
Pharmacokinetic
+2 more
Other study objectives
Type I Interferon signature

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: MEDI7734Active Control1 Intervention
Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
Group II: PlaceboPlacebo Group1 Intervention
One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.

Find a Location

Who is running the clinical trial?

Viela BioLead Sponsor
12 Previous Clinical Trials
1,068 Total Patients Enrolled
MedImmune LLCIndustry Sponsor
347 Previous Clinical Trials
788,721 Total Patients Enrolled
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top